PT - JOURNAL ARTICLE AU - Pannus, Pieter AU - Neven, Kristof Y AU - De Craeye, Stéphane AU - Heyndrickx, Leo AU - Kerckhove, Sara Vande AU - Georges, Daphnée AU - Michiels, Johan AU - Francotte, Antoine AU - Van Den Bulcke, Marc AU - Zrein, Maan AU - Van Gucht, Steven AU - Schmickler, Marie-Noëlle AU - Verbrugghe, Mathieu AU - Matagne, André AU - Thomas, Isabelle AU - Dierick, Katelijne AU - Weiner, Joshua A. AU - Ackerman, Margaret E. AU - Goriely, Stanislas AU - Goossens, Maria E AU - Ariën, Kevin K. AU - Desombere, Isabelle AU - Marchant, Arnaud TI - Poor antibody response to BioNTech/Pfizer COVID-19 vaccination in SARS-CoV-2 naïve residents of nursing homes AID - 10.1101/2021.06.08.21258366 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.08.21258366 4099 - http://medrxiv.org/content/early/2021/06/09/2021.06.08.21258366.short 4100 - http://medrxiv.org/content/early/2021/06/09/2021.06.08.21258366.full AB - Background Residents of nursing homes (NH) are at high risk of COVID-19 related morbidity and death and may respond poorly to vaccination because of old age and frequent comorbidities.Methods Forty residents and forty staff members either naïve or previously infected with SARS-CoV-2 were recruited in two NH in Belgium before immunization with two doses of 30µg BNT162b2 mRNA vaccine at day 0 and day 21. Binding antibodies (Ab) to SARS-CoV-2 receptor binding domain (RBD), spike domains S1 and S2, RBD Ab avidity, and neutralizing Ab against SARS-CoV-2 wild type and B.1.351 variant were assessed at days 0, 21, 28, and 49.Results SARS-CoV-2 naïve residents had lower Ab responses to BNT162b2 mRNA vaccination than naïve staff. These poor responses involved lower levels of IgG to all domains of the vaccine antigen, lower avidity of RBD IgG, and lower levels of Ab neutralizing the vaccine strain. No naïve resident had detectable neutralizing Ab to the B.1.351 variant. High and comparable Ab responses were observed in residents and staff previously infected with SARS-CoV-2. Clustering analysis revealed that poor vaccine responders not only included naïve residents but also naïve staff, emphasizing the heterogeneity of responses to mRNA vaccination in the general population.Conclusions The poor Ab responses to mRNA vaccination observed in infection naïve residents and in some naïve staff members of NH suggest suboptimal protection against breakthrough infection, especially with variants of concern. Adapted vaccination regimens may be needed to provide optimal protection against COVID-19 to vulnerable populations.Summary Poor antibody responses to COVID-19 mRNA vaccination were observed in SARS-CoV-2 infection naïve residents and some naïve staff members of nursing homes. This suggests suboptimal protection against breakthrough infection, especially with variants of concern, and the need for adapted vaccination regimens.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04527614Funding StatementThis work was supported by the Belgian Federal Government [COVID-19_SC004, COVID-19_SC049, COVID-19_SC059]; the European Regional Development Fund of the Walloon Region (Wallonia-Biomed portfolio) [411132-957270]; and the Flemish Research Foundation [grant number FWO-G0G4220N to K. K. A.].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of the Hopital Erasme, Brussels, Belgium (reference B4062020000134) and the Federal Agency for Medicines and Health Products (2021-000401-24).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll study data is stored on a secured central server of Sciensano.